A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

NCT06240728 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Malignant Neoplasm

Interventions

DRUG: NPX887

Sponsor

NextPoint Therapeutics, Inc.